↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Engelholm SA) "

Sökning: WFRF:(Engelholm SA)

Resultat 1-3 av 3

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Bojesen, SE, et al. (författare) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer 2013 Ingår i: Nature genetics. - New york : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 45:4, s. 371-384 Tidskriftsartikel (refereegranskat)
2.	Southey, MC, et al. (författare) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS 2016 Ingår i: Journal of medical genetics. - : BMJ. - 1468-6244 .- 0022-2593. ; 53:12, s. 800-811 Tidskriftsartikel (refereegranskat)
3.	Gronlund, B, et al. (författare) Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane - Results from a multicenter phase I/II study 2005 Ingår i: Cancer. - : Wiley. - 1097-0142 .- 0008-543X. ; 103:7, s. 1388-1396 Tidskriftsartikel (refereegranskat)abstract BACKGROUND. The objectives of this study were to determine the maximum tolerable dose (MTD), toxicity, efficacy, and feasibility of a sequential regimen of fixed-dose topotecan (1.00 mg/m(2) on Days 1-5) and increasing doses of oral etoposide (50 mg, 75 mg, and 100 mg on Days 6-12 or Days 6-19) in patients with recurrent ovarian carcinoma. METHODS. This multicenter, open-label study was planned as a Phase I-II study that included patients with epithelial ovarian carcinoma who failed or who developed recurrent disease < 12 months after the end of platinum and taxane-containing chemotherapy. Dose-limiting toxicity (DLT) was defined as follows: Grade 4 neutropenia for > 1 week, or neutropenic fever 38.5 degrees C for > 24 hours/sepsis, or Grade 4 thrombocytopenia for > 1 week, or thrombocytopenia with bleeding, or Grade 3-4 nonhematologic toxicity. RESULTS. The MTD, as defined in the protocol, could not be settled because of unpredictable toxicity, because DLT was found at all dose levels except the starting dose level. In 28 patients (Phase I), 155 cycles were evaluable for toxicity. The main DLT was neutropenia Grade 4 for > 1 week or neutropenic fever/sepsis. Overall, neutropenia Grade 4 that lasted > 1 week and sepsis were noticed in 3% and 2% of cycles, respectively. Because no MTD was reached, the planned Phase II trial was not initiated. However, the patients from Phase I were followed until they developed progressive disease and, among them, 9 patients (32%) obtained an objective response (according to Response Evaluation Criteria in Solid Tumors (RECIST) or CA125 response criteria). CONCLUSIONS. Combined topotecan and oral etoposide was inappropriate in patients with recurrent ovarian carcinoma because of unpredictable hematologic toxicity. However, the high objective response rate highlighted the potential additive effect of topoisomerase I and II inhibitors.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-3 av 3

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (3)

Typ av innehåll: refereegranskat (3)

Författare/redaktör: Butzow, R (2); Jones, M. (2); Zheng, W. (2); Benitez, J. (2); Miller, N (2); Brenner, H (2); visa fler...; Dennis, J (2); Bernard, L. (2); Blomqvist, C (2); MCLAUGHLIN, JR (2); Cai, H. (2); Shu, XO (2); Hall, P (2); Humphreys, K (2); Czene, K (2); Lindblom, A (2); Peterlongo, P (2); Anton-Culver, H (2); Giles, GG (2); Milne, RL (2); Alvarez, N (2); Hartmann, A (2); Michailidou, K (2); Pita, G (2); Bolla, MK (2); Margolin, S (2); Swerdlow, A (2); Ashworth, A (2); Orr, N (2); Tomlinson, I (2); Hopper, JL (2); Southey, MC (2); Brauch, H (2); Bruning, T (2); Hamann, U (2); Dunning, AM (2); Knight, JA (2); Glendon, G (2); Schmidt, MK (2); Broeks, A (2); Fasching, PA (2); Beckmann, MW (2); Wu, AH (2); Van Den Berg, D (2); Cox, A (2); Muir, K (2); Radice, P (2); Yannoukakos, D (2); Fletcher, O (2); Peto, J (2); visa färre...

Lärosäte: Lunds universitet (2); Karolinska Institutet (2); Umeå universitet (1)

Språk: Engelska (3)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy